TPST Tempest Therapeutics, Inc.
Company Analysis
Latest News
Tempest Therapeutics Receives Nasdaq Delisting Notice; Plans to Appeal
Tempest Therapeutics (TPST) announced it received a delisting notice from The Nasdaq Stock Market on November 17, 2026. The notice was issued because the...
Tempest Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 18, 2026
Analysts expect Tempest Therapeutics to report zero revenue and a consensus EPS loss of $0.32 for Q3 2026, while the $0.74 stock price continues to trade at a...
Tempest Therapeutics Shareholders Approve Key Stock Issuance and Financing Proposals
Tempest Therapeutics, Inc. announced that its stockholders have approved several key proposals at its 2026 Annual Meeting, including the potential issuance of...
Tempest Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Tempest Therapeutics is expected to report a Q3 2026 net loss of $0.32 per share on zero revenue, with the stock currently trading at $1.42, significantly...
Tempest Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Wall Street analysts expect Tempest Therapeutics to report a consensus EPS of -$0.32 on zero revenue for Q3 2026, with the current stock price of $0.51 trading...
Tempest Therapeutics Appoints New CFO Following Immediate Resignation of Predecessor
Tempest Therapeutics announced the immediate resignation of Chief Financial Officer Constance Ames and the concurrent appointment of Stephanie Horn-Warnock as...